Affordable Access

Access to the full text

Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature

  • Safa, Houssein1
  • Johnson, Daniel H1
  • Trinh, Van Anh1
  • Rodgers, Theresa E1
  • Lin, Heather1
  • Suarez-Almazor, Maria E1
  • Fa’ak, Faisal2
  • Saberian, Chantal1
  • Yee, Cassian1
  • Davies, Michael A1
  • Tummala, Sudhakar1
  • Woodman, Karin1
  • Abdel-Wahab, Noha1, 3
  • Diab, Adi1
  • 1 The University of Texas MD Anderson Cancer Center, Houston, TX, USA , Houston (United States)
  • 2 Piedmont Athens Regional Medical Center, Athens, Georgia , Athens (Georgia)
  • 3 Assiut University Hospitals, Assiut, Egypt , Assiut (Egypt)
Published Article
Journal for ImmunoTherapy of Cancer
Springer (Biomed Central Ltd.)
Publication Date
Nov 21, 2019
DOI: 10.1186/s40425-019-0774-y
Springer Nature


BackgroundMyasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). Given the limited evidence, data from a large cohort of patients is needed to aid in recognition and management of this fatal complication.MethodsWe reviewed our institutional databases to identify patients who had cancer and MG in the setting of ICI. We systematically reviewed the literature through August 2018 to identify all similar reported patients. We collected data on clinical and diagnostic features, management, and outcomes of these cases.ResultsSixty-five patients were identified. Median age was 73 years; 42 (65%) were males, 31 (48%) had metastatic melanoma, and 13 (20%) had a preexisting MG before ICI initiation. Most patients received anti-PD-1 (82%). Sixty-three patients (97%) developed ICI-related MG (new onset or disease flare) after a median of 4 weeks (1 to 16 weeks) of ICI initiation. Twenty-four patients (37%) experienced concurrent myositis, and respiratory failure occurred in 29 (45%). ICI was discontinued in 61 patients (97%). Death was reported in 24 patients (38%); 15 (23%) due to MG complication. A better outcome was observed in patients who received intravenous immunoglobulin (IVIG) or plasmapheresis (PLEX) as first-line therapy than in those who received steroids alone (95% vs 63% improvement of MG symptoms, p = 0.011).ConclusionsMG is a life-threatening adverse event of acute onset and rapid progression after ICI initiation. Early use of IVIG or PLEX, regardless of initial symptoms severity, may lead to better outcomes than steroids alone. Our data suggest the need to reassess the current recommendations for management of ICI-related MG until prospective longitudinal studies are conducted to establish the ideal management approach for these patients.

Report this publication


Seen <100 times